SpringerLink
Log in

Crizotinib-induced simultaneous multiple cardiac toxicities

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines:  the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801

    Article  PubMed  Google Scholar 

  3. Deshpande H, Marler V, Sosa JA (2011) Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco Targets Ther 4:209–215

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Gallo S, Sala V, Gatti S, Crepaldi T (2015) Cellular and molecular mechanisms of HGF/met in the cardiovascular system. Clin Sci (Lond) 129:1173–1193

    Article  CAS  Google Scholar 

  5. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33:2667–2674

    Article  PubMed  CAS  Google Scholar 

Download references

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Author information

Authors and Affiliations

  1. Division of Cardiology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Takuya Oyakawa, Nao Muraoka & Kei Iida

  2. Research Institute, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Masatoshi Kusuhara

  3. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Takahisa Kawamura, Tateaki Naito & Toshiaki Takahashi

Authors
  1. Takuya Oyakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nao Muraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kei Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masatoshi Kusuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahisa Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tateaki Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuya Oyakawa.

Ethics declarations

Conflict of interest

Takuya Oyakawa reports personal fees from Bristol-Myers Squibb, personal fees from Sumitomo Dainippon Pharma, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from BAYER, outside the submitted work; .

Nao Muraoka has nothing to disclose.

Kei Iida has nothing to disclose.

Masatoshi Kusuhara has nothing to disclose.

Takahisa Kawamura has nothing to disclose.

Tateaki Naito has nothing to disclose.

Toshiaki Takahashi has nothing to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oyakawa, T., Muraoka, N., Iida, K. et al. Crizotinib-induced simultaneous multiple cardiac toxicities. Invest New Drugs 36, 949–951 (2018). https://doi.org/10.1007/s10637-018-0605-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-018-0605-x

Keywords

Search

Navigation